In this phase 3 RCT, the percentage of pts with recurrent #Cdiff was 12% in the SER-109 group and 40% in the placebo group (RR: 0.32; 95% CI: 0.18 to 0.58; P

Nine months ago my world was turned upside down. I was prescribed an antibiotic for a wisdom tooth procedure. Five days later I woke up to the worst pain of my life. After two days of pure misery crying on my bathroom floor, I went into urgent care. The doctor …

Interesting. Important to note ⬆️ vanc levels in human faeces are in xs of MICs. Ribotyping would answer whether expansion of single ribotype or more. @HCAILeeds and @SmitsLab optimising #Cdiff susceptibility testing methods in @ESCMID sponsored project. @EUCAST_EUCAST— Jane Freeman (@drjanefreeman) January 15, 2022

Nature Reviews Microbiology - Microbiome-based therapeutics hold great promise for reducing disease susceptibility and enhancing disease resistance. In this Review, Sorbara and Pamer explore the...

Background Neutropenia and antibiotic use put patients at risk for Clostridioides difficile infection (CDI) following allogenic hematopoietic cell transplant (alloHCT). CDI following alloHCT has bee...

C. difficile strains exhibiting reduced susceptibility to vancomycin are currently circulating in patient populations. The spread of strains resistance to vancomycin, a first-line antibiotic for CDI, poses a serious therapeutic challenge. Routine susceptibility testing may be necessary.

The approval is based on results from the ENVISION I Phase 3 study, which showed biologic use linked to clinical remission and maintenance in patients.

Oral vancomycin was associated with reduced CDI incidence in patients that underwent an alloHCT without negatively affecting post-transplant outcomes. The contribution of confounders cannot be excluded. This article is protected by copyright. All rights reserved.

Panelists review unmet needs in clostridium difficile infection management and consider how medical policies are evolving to address them.

Closing out their discussion on Clostridioides difficile infection, panelists share closing thoughts on novel pipeline therapies.

Closing out their discussion on Clostridioides difficile infection, panelists share closing thoughts on novel pipeline therapies.

Closing out their discussion on Clostridioides difficile infection, panelists share closing thoughts on novel pipeline therapies.

The anaerobic, gastrointestinal pathogen Clostridioides difficile can cause severe forms of enterocolitis which is mainly mediated by the toxins it produces. The RNA polymerase inhibitor Fidaxomicin is the current gold standard for the therapy of C. difficile infections due to several beneficial fea …

The composition of the gut microbiota is highly dynamic and changes according to various conditions. The gut microbiota mainly includes difficult-to-cultivate anaerobic bacteria, hence knowledge about its composition has significantly arisen from culture-independent methods based on next-generation …

Clinical care is evolving in this area and shows promise in the various modalities and therapies that are going through clinical trials.

We reviewed C.difficile positive patients discharged on fidaxomicin after local adoption of 2021C.difficile infection (CDI) guidelines. From June 14 - Oct 3, 2021, 80% (12/15) had copayments $0-$35, and 27% (4/15) required prior authorization. The 30-day CDI recurrence was 7%.

Reading Time: 4 minutes The Pre-brief Clostridioides difficile is a gram-positive anaerobic bacillus that produces spores as well as exotoxins, toxin A and toxin B.…

The results are likely specific to areas without hypervirulent strains of Clostridioides difficile, such as #Australia. #cdiffhttps://t.co/UYlw3BfV3j— Contagion (@Contagion_Live) December 6, 2021

Shared insight on the differences between ACG and IDSA/SHEA treatment guidelines for patients with clostridium difficile infection.

Also known as C. diff for short, Clostridium difficile is an extremely difficult intestinal disease to manage…but not an impossible one. Joining Dr. Neil Nandi to share her insights on how to best mange C. diff in IBD patients is Dr. Jessica Allegretti, the Associate Director of the Crohn's and Colitis Center and the Director of the Fecal Microbiota Transplant Program at the Brigham and Women's Hospital in Boston, Massachusetts.

A panel of experts review treatment goals and assessing response in patients with recurrent clostridium difficile infection.

In this study, increasing CDI trends in annual cohorts of SOT recipients were observed. Posttransplant CDI was associated with mortality, and late-onset CDI was associated with a greater risk of death than early-onset CDI. These findings suggest that preventive strategies should not be limited to th …